PURPOSE To provide evidence-based recommendations to practicing clinicians on
management of patients with stage III non–small-cell lung cancer (NSCLC). METHODS An …

Despite the rapidly evolving treatment landscape in advanced non-small-cell lung cancer
(NSCLC), developments in neoadjuvant and adjuvant treatments have been nascent by …

Background Approximately 20% of patients with non–small-cell lung cancer (NSCLC)
receive a diagnosis of stage III disease. There is no current consensus regarding the most …

Lung cancer is the leading cause of cancer mortality worldwide with 1.8 million newly
diagnosed cases, or 13% of all cancers diagnosed, in 2012 [1]. The worldwide numbers are …

Tumors are characterized by somatic mutations that drive biological processes ultimately
reflected in tumor phenotype. With regard to radiographic phenotypes, generally …

Abstract Magnetic Resonance-guided radiotherapy (MRgRT) marks the beginning of a new
era. MR is a versatile and suitable imaging modality for radiotherapy, as it enables direct …

Surgery remains the only potentially curative modality for early-stage non-small cell lung
cancer (NSCLC) patients and tissue availability is made possible. However, a proportion of …

Non-small-cell lung cancer is one of the leading causes of deaths from cancer worldwide.
Therefore, improvements in diagnostics and treatments are urgently needed. In this review …

Improvements in outcomes for patients with resectable lung cancers have plateaued.
Clinical trials of resectable non-small-cell lung cancers with overall survival as the primary …

Background One of the standard options in the treatment of stage IIIA/N2 non-small-cell lung
cancer is neoadjuvant chemotherapy and surgery. We did a randomised trial to investigate …